Phreesia upgraded by RBC Capital Mkts with a new price target
$PHR
Business Services
Consumer Discretionary
RBC Capital Mkts upgraded Phreesia from Sector Perform to Outperform and set a new price target of $32.00 from $24.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/8/2025 | $24.00 → $32.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 2/26/2024 | $35.00 | Buy | Truist |
| 1/17/2024 | $30.00 → $32.00 | Neutral → Buy | DA Davidson |
| 1/3/2024 | $29.00 | Overweight | Barclays |
| 4/12/2023 | $37.00 | Overweight | Stephens |
| 1/4/2023 | $35.00 → $40.00 | Buy | Needham |
| 12/13/2022 | $40.00 | Neutral → Buy | Citigroup |
| 12/9/2022 | $31.00 → $34.00 | Mkt Perform → Outperform | SVB Leerink |
4 - Phreesia, Inc. (0001412408) (Issuer)
4 - Phreesia, Inc. (0001412408) (Issuer)
4 - Phreesia, Inc. (0001412408) (Issuer)
Phreesia, a leader in patient intake, outreach and activation, has been named to G2's 2025 Best Software Awards in the Best Healthcare Software Products category. As the world's largest and most trusted software marketplace, G2 reaches 100 million buyers annually. Its annual Best Software Awards rank the world's best software companies and products based on authentic, timely reviews from real users. Phreesia's digital solutions enhance the patient experience and drive efficiency for healthcare providers. "We are incredibly honored to receive this award from G2, especially because it's based on first-hand feedback directly from our clients," said Phreesia CEO Chaim Indig. "We're committed t
Phreesia, Inc. (NYSE:PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal fourth quarter and fiscal year ended January 31, 2025. "We are pleased with our solid finish to fiscal 2025 and I am excited about the new products we have introduced over the past several quarters that improve medication adherence and the overall patient and provider experience," said CEO and Co-Founder Chaim Indig. Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q4 Fiscal 2025 Stakeholder Letter. Fiscal Fourth Quarter Ended January 31, 2025 Highlights Total revenue was $109.7 million in the quarter, up 15% year-over-year. Average num
Phreesia, a leader in patient intake, outreach and activation, is proud to announce that Sally Thayer, Vice President of Product Management, has been named to The Software Report's list of the Top 50 Women Leaders in Software of 2024. Honorees were chosen based on their leadership and contributions to the software industry. This is the seventh consecutive year a female leader from Phreesia has been named to the list. Previous Phreesia awardees include Allison Hoffman, General Counsel; Kristin Roberts, Vice President of Product Management; and Amy VanDuyn, Senior Vice President of Human Resources. "Much as these companies are breaking down barriers in the business, these women are breaki
SC 13G/A - Phreesia, Inc. (0001412408) (Subject)
SC 13G/A - Phreesia, Inc. (0001412408) (Subject)
SC 13G/A - Phreesia, Inc. (0001412408) (Subject)
Phreesia will work with the NAI to shape the national conversation around data privacy and promote consumer choice and transparency As part of the company's ongoing commitment to consumer data privacy, Phreesia is pleased to announce it has joined the Network Advertising Initiative (NAI), a non–profit organization and the leading self-regulatory association dedicated to responsible data collection and use for digital advertising. As a member, Phreesia will work with the NAI to promote consumer-centric privacy practices in healthcare and take a leadership role in shaping the national conversation around data privacy. "We are excited to join the NAI, an organization that shares our dedicati
Phreesia, a leader in patient intake, outreach and activation, is proud to announce that Audrey Gato, Vice President of Client Solutions, has been named to The Software Report's list of the Top 50 Women Leaders in SaaS of 2023. Honorees were chosen based on their leadership and contributions to the Software-as-a-Service industry. This is the sixth consecutive year a female leader from Phreesia has been named to the list. Previous Phreesia awardees include Allison Hoffman, General Counsel; Kristin Roberts, Vice President of Product Management; Kharen Hauck, Vice President of Marketing; Amy VanDuyn, Senior Vice President of Human Resources; and Sara DiNardo, Vice President of Client Solutio
SCHEDULE 13G/A - Phreesia, Inc. (0001412408) (Subject)
SCHEDULE 13G/A - Phreesia, Inc. (0001412408) (Subject)
144 - Phreesia, Inc. (0001412408) (Subject)
Phreesia, Inc. (NYSE:PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal fourth quarter and fiscal year ended January 31, 2025. "We are pleased with our solid finish to fiscal 2025 and I am excited about the new products we have introduced over the past several quarters that improve medication adherence and the overall patient and provider experience," said CEO and Co-Founder Chaim Indig. Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q4 Fiscal 2025 Stakeholder Letter. Fiscal Fourth Quarter Ended January 31, 2025 Highlights Total revenue was $109.7 million in the quarter, up 15% year-over-year. Average num
Phreesia, Inc. (NYSE:PHR) ("Phreesia") today announced that it will release its fiscal fourth quarter and fiscal year 2025 financial results after the close of market trading on Wednesday, March 12, 2025. Phreesia will issue a press release announcing its quarterly and full year results and the company's quarterly stakeholder letter, both of which will be posted on its investor website at ir.phreesia.com. Phreesia will then hold a conference call to discuss its fiscal fourth quarter and fiscal year 2025 results starting at 5PM Eastern Time on the same day. To participate in the company's live conference call and webcast, please dial (800) 715-9871, or (646) 307-1963 for international part
Phreesia, Inc. (NYSE:PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal third quarter ended October 31, 2024. "We are excited about the future here at Phreesia," said CEO and Co-Founder Chaim Indig. "Our network continues to grow, adoption of our current offerings is increasing, and we are beginning to see the promise of new solutions we are investing in." Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q3 Fiscal Year 2025 Stakeholder Letter. Fiscal Third Quarter Ended October 31, 2024 Highlights Total revenue was $106.8 million in the quarter, up 17% year-over-year. Average number of healthcare servi
RBC Capital Mkts upgraded Phreesia from Sector Perform to Outperform and set a new price target of $32.00 from $24.00 previously
Truist initiated coverage of Phreesia with a rating of Buy and set a new price target of $35.00
DA Davidson upgraded Phreesia from Neutral to Buy and set a new price target of $32.00 from $30.00 previously